News
FDA plans to limit COVID vaccine to only high-risk people
Digest more
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.
Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.
While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...
This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...
Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID ...
The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for ...
JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback